New Advanced Retinal Imaging Platform Unveiled at Mauriziano Hospital in Turin
On Monday, February 12, 2024, the ophthalmology clinic at the Mauriziano hospital in Turin unveiled the Optos Silverstone, the latest and most advanced multimodal platform for wide-field retinal imaging. This cutting-edge technology was funded by the La Stampa – Specchio dei Tempi Foundation at a value of approximately 291 thousand euros.
The World Health Organization estimates that there are over two billion people with visual impairment worldwide, and about half of these cases are preventable. The main causes of blindness globally are uncorrected refractive errors and cataracts, followed by retinopathy and glaucoma. The social cost of low vision worldwide is over 400 billion euros per year.
In industrialized countries, retinal diseases represent the main cause of blindness due to the aging population and increased incidence of systemic pathologies involving the eye. This makes the Optos Silverstone platform a crucial resource for reference centers for the treatment of retinal diseases. The platform, implemented with the new release for non-invasive analysis of the retinal vasculature from the center to the extreme periphery, provides comprehensive information and improves the ability to decide when to subject patients to treatment.
The new platform also allows for the reduction of serious and disabling forms of retinal diseases in over 50% of cases. Dr. Francesco Faraldi, the director of the ophthalmology clinic at the Mauriziano hospital, emphasized that this technology will pave the way for the advantages offered by artificial intelligence and new organizational models of multidisciplinary patient care.
The ophthalmology department at the Mauriziano hospital has undergone a process of progressive reorganization in recent years, with the implementation of pediatric ophthalmology and strabismus service, the opening of a cornea transplant center, and the activation of a reference for uveitis. The Optos Silverstone platform will further improve the diagnosis and treatment of maculopathies, as well as hereditary retinal diseases such as retinitis pigmentosa.
This new technology represents a significant advancement in the integration of diagnostic techniques and will improve the pre- and post-operative phases of treatments for surgical maculopathies. With its ability to rapidly and in-depth study central prognostic biomarkers and peripheral alterations, the Optos Silverstone platform is poised to revolutionize the way retinal diseases are diagnosed and treated.
For more news and updates, continue reading TorinoToday and follow our Facebook page and subscribe to our WhatsApp channel.